About Nexalin Technology, Inc. - Common Stock (NXL)
Nexalin Technology, Inc. is a publicly traded company focused on the development and commercialization of innovative therapeutic technologies designed to improve mental health and wellness. The company specializes in non-invasive neurostimulation therapies that target various mental health conditions, offering potential alternative treatment options. By integrating advanced technology with a commitment to research and development, Nexalin aims to enhance the quality of life for individuals seeking effective solutions to manage their mental health challenges. Read More
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
HOUSTON, TX, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on September 9, 2025, at 4:15 p.m. ET.
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, as Chief Financial Officer, effective August 1, 2025.
ORLANDO, FL / ACCESS Newswire / May 30, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and FatPipe, Inc. (Nasdaq:FATN) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, May 31, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.m. ET.
HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin’s strategic prioritization of Alzheimer’s disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
